What Is Quality by Design and Why China's Pharma Sector Relies on ItUntitledA Science-Led Route to Consistent Quality
Quality by Design (QbD) Training in China is a practical, non-certification programme that teaches pharmaceutical and biopharmaceutical professionals to build quality into a product from the design stage rather than testing it in at the end. It is grounded in the ICH Q8(R2), Q9, Q10 and Q11 guidelines that China's National Medical Products Administration adopted after the country joined the ICH in 2017. Over an intensive one-day programme you work through the full QbD workflow: defining the Quality Target Product Profile (QTPP), identifying Critical Quality Attributes, running Ishikawa and FMEA risk assessment, using Design of Experiments to map the design space, applying Process Analytical Technology, and building a control strategy for regulatory submission. Hands-on exercises use realistic development scenarios. The training suits formulation, process, analytical, quality and CMC regulatory professionals across China's drug makers, CDMOs and biotech clusters. As reviewers increasingly expect QbD evidence and Chinese innovators expand globally, these skills are a clear advantage. Start building right-first-time development capability with Invensis Learning.










